February 26, 2018
DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma surgery. Terms of the agreement were not disclosed.
“Orthobiologics will continue to evolve to meet the needs of patients, surgeons and payers and Bioventus is pleased to begin work on the next generation of bone graft solutions with LifeLink,” said Tony Bihl, CEO of Bioventus. “This approach is consistent with our strategy to grow sales of our existing products in the surgical orthobiologics space and expand our offering with new product innovations.”
“The gift of tissue donation is invaluable and offers the opportunity to benefit so many patients in need,” said Jean Davis, President and CEO of LifeLink Foundation, Inc. “Companies like Bioventus are helping to further enhance the immeasurable impact of tissue donations by investing in R&D to bring new solutions to the market and we are excited for our research teams to collaborate together on this development initiative.”
LifeLink Foundation, an independent, non-profit community service organization is dedicated to the recovery and transplantation of organs and tissue. The Foundation is made up of five divisions: LifeLink Tissue Bank, which recovers and processes tissue for patients in need; LifeLink of Florida, LifeLink of Georgia, and LifeLink of Puerto Rico, three federally-certified organ procurement organizations; and LifeLink Transplantation Immunology Laboratory, which supports 15 organ-specific transplant programs. Additionally, the LifeLink Legacy Fund supports the LifeLink Foundation mission through patient assistance, research and programmatic grants to improve organ and tissue donation, and transplantation. Learn more about LifeLink Foundation at www.LifeLinkFoundation.org or LifeLink Tissue Bank at www.LifeLinkTB.org.
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Orthobiologic products from Bioventus include offerings for bone healing, bone graft and knee osteoarthritis. Its EXOGEN Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSI, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.
Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo and EXOGEN are registered trademarks of Bioventus LLC.
Thomas Hill, 919-474-6715